Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of Endothelin-1 in Insulin-stimulated Blood Flow in Obesity
NCT05518422Phase 1Withdrawn
- Sponsor
- University of Missouri
- Start
- Feb 2024
- Primary completion
- Feb 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of bosentan in obesity, sponsored by University of Missouri. Primary endpoints: Muscle Sympathetic Nerve Activity and Leg Blood Flow. Planned start Feb 2024; status: withdrawn.
02
Drugs
bosentan
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05518422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518422.